Publications

Export 1643 results:
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is S  [Clear All Filters]
2019
McEwen LM, O'Donnell KJ, McGill MG, Edgar RD, Jones MJ, MacIsaac JL, Lin DTse Shen, Ramadori K, Morin A, Gladish N et al..  2019.  The PedBE clock accurately estimates DNA methylation age in pediatric buccal cells.. Proc Natl Acad Sci U S A.
Josephy-Hernandez S, Pirvulescu I, Maira M, Aboulkassim T, Wong TPan, R McKinney A, H Saragovi U.  2019.  Pharmacological interrogation of TrkA-mediated mechanisms in hippocampal-dependent memory consolidation.. PLoS One. 14(6):e0218036.
Belzeaux R, Fiori LM, Lopez JPablo, Boucekine M, Boyer L, Blier P, Farzan F, Frey BN, Giacobbe P, Lam RW et al..  2019.  Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment.. J Clin Psychiatry. 80(3)
Sapkota RP, Brunet A, Kirmayer LJ.  2019.  Predictors of Dissociative Experiences Among Adolescents in Nepal: A Path Analysis.. J Nerv Ment Dis.
Simo B, Caron J., Bamvita JM, Grenier G, MJ Fleury.  2019.  Predictors of Number of Healthcare Professionals Consulted by Individuals with Mental Disorders or High Psychological Distress.. Int J Environ Res Public Health. 16(17)
Miguel PMaidana, Pereira LOrlandi, Barth B, Filho EJosé de M, Pokhvisneva I, Nguyen TTT, Garg E, Razzolini BRegis, Koh DXin Ping, Gallant H et al..  2019.  Prefrontal Cortex Dopamine Transporter Gene Network Moderates the Effect of Perinatal Hypoxic-Ischemic Conditions on Cognitive Flexibility and Brain Gray Matter Density in Children.. Biol Psychiatry.
Miguel PMaidana, Pereira LOrlandi, Barth B, Filho EJosé de M, Pokhvisneva I, Nguyen TTT, Garg E, Razzolini BRegis, Koh DXin Ping, Gallant H et al..  2019.  Prefrontal Cortex Dopamine Transporter Gene Network Moderates the Effect of Perinatal Hypoxic-Ischemic Conditions on Cognitive Flexibility and Brain Gray Matter Density in Children.. Biol Psychiatry.
Sauvé G, Brodeur MB, Shah JL, Lepage M.  2019.  The Prevalence of Negative Symptoms Across the Stages of the Psychosis Continuum.. Harv Rev Psychiatry. 27(1):15-32.
Sauvé G, Brodeur MB, Shah JL, Lepage M.  2019.  The Prevalence of Negative Symptoms Across the Stages of the Psychosis Continuum.. Harv Rev Psychiatry. 27(1):15-32.
Lutgens D, Joober R, Iyer S, Lepage M, Norman R, Schmitz N, Mustafa S, Abadi S, Malla A.  2019.  Progress of negative symptoms over the initial 5 years of a first episode of psychosis.. Psychol Med. 49(1):66-74.
Olsen RK, Carr VA, Daugherty AM, La Joie R, Amaral RSC, Amunts K, Augustinack JC, Bakker A, Bender AR, Berron D et al..  2019.  Progress update from the hippocampal subfields group.. Alzheimers Dement (Amst). 11:439-449.
Olsen RK, Carr VA, Daugherty AM, La Joie R, Amaral RSC, Amunts K, Augustinack JC, Bakker A, Bender AR, Berron D et al..  2019.  Progress update from the hippocampal subfields group.. Alzheimers Dement (Amst). 11:439-449.
Olsen RK, Carr VA, Daugherty AM, La Joie R, Amaral RSC, Amunts K, Augustinack JC, Bakker A, Bender AR, Berron D et al..  2019.  Progress update from the hippocampal subfields group.. Alzheimers Dement (Amst). 11:439-449.
Olsen RK, Carr VA, Daugherty AM, La Joie R, Amaral RSC, Amunts K, Augustinack JC, Bakker A, Bender AR, Berron D et al..  2019.  Progress update from the hippocampal subfields group.. Alzheimers Dement (Amst). 11:439-449.
Olsen RK, Carr VA, Daugherty AM, La Joie R, Amaral RSC, Amunts K, Augustinack JC, Bakker A, Bender AR, Berron D et al..  2019.  Progress update from the hippocampal subfields group.. Alzheimers Dement (Amst). 11:439-449.
Zhang XMin, François U, Silm K, Angelo MFlorencia, Fernandez-Busch MVictoria, Maged M, Martin C, Bernard V, Cordelières FP, Deshors M et al..  2019.  A proline-rich motif on VGLUT1 reduces synaptic vesicle super-pool and spontaneous release frequency.. Elife. 8
Schirrmacher R, Bailey JJ, Mossine AV, Scott PJH, Kaiser L, Bartenstein P, Lindner S, Kaplan DR, Kostikov A, Fricker G et al..  2019.  Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging.. Pharmaceuticals (Basel). 12(1)
Schirrmacher R, Bailey JJ, Mossine AV, Scott PJH, Kaiser L, Bartenstein P, Lindner S, Kaplan DR, Kostikov A, Fricker G et al..  2019.  Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging.. Pharmaceuticals (Basel). 12(1)
Schirrmacher R, Bailey JJ, Mossine AV, Scott PJH, Kaiser L, Bartenstein P, Lindner S, Kaplan DR, Kostikov A, Fricker G et al..  2019.  Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging.. Pharmaceuticals (Basel). 12(1)
Schirrmacher R, Bailey JJ, Mossine AV, Scott PJH, Kaiser L, Bartenstein P, Lindner S, Kaplan DR, Kostikov A, Fricker G et al..  2019.  Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging.. Pharmaceuticals (Basel). 12(1)
Wang JL, MacQueen G, Patten S, Manuel D, Lashewicz B, Schmitz N.  2019.  A randomized controlled trial to examine the impacts of disclosing personalized depression risk information on the outcomes of individuals who are at high risk of developing major depression: a research protocol.. BMC Psychiatry. 19(1):285.
Ng KPin, Therriault J, Kang MSu, Struyfs H, Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Massarweh G, Soucy J-P et al..  2019.  Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [F]THK5351 uptake in progressive supranuclear palsy.. Neuroimage Clin. 24:102091.
Ng KPin, Therriault J, Kang MSu, Struyfs H, Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Massarweh G, Soucy J-P et al..  2019.  Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [F]THK5351 uptake in progressive supranuclear palsy.. Neuroimage Clin. 24:102091.
Ng KPin, Therriault J, Kang MSu, Struyfs H, Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Massarweh G, Soucy J-P et al..  2019.  Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [F]THK5351 uptake in progressive supranuclear palsy.. Neuroimage Clin. 24:102091.
Yung AR, Wood SJ, Malla A, Nelson B, McGorry P, Shah J.  2019.  The reality of at risk mental state services: a response to recent criticisms.. Psychol Med. :1-7.

Pages